Helsinn Therapeutics (U.S.), Inc
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
25%
3 trials in Phase 3/4
55%
6 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
Role: collaborator
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Role: lead
The Role of Ghrelin in Cancer Cachexia
Role: collaborator
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Role: lead
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Role: lead
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Role: lead
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
Role: lead
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
Role: lead
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Role: lead
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
Role: lead
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Role: lead
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
Role: lead
All 12 trials loaded